drugset / Trial / NCT03069508
Clemizole HCl for Subjects With Hepatocellular Carcinoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is a phase IIa open label pilot study of up to six months treatment with clemizole hydrochloride (200 mg vs. 300 mg vs. 400 vs. 500 mg mg) given orally TID to subjects with hepatocellular carcinoma that are either awaiting transplantation or have an unresectable lesion.
Timeline
- Start
- 2017-02-13
- Primary completion
- 2017-12-31
- Completion
- 2018-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clemizole | Small molecule | 200 mg | Oral |
| Subject | Clemizole | Small molecule | 300 mg | Oral |
| Subject | Clemizole | Small molecule | 400 mg | Oral |
| Subject | Clemizole | Small molecule | 500 mg | Oral |